Biomarker Development
The Biomarker Development Team looks for new biomarkers in preclinical development and exploratory clinical development that may be exploited as readouts in clinical trials or used as predictors of safety and efficacy during preclinical studies.
They focus on safety and efficacy biomarkers for preclinical trials, exploratory clinical studies and clinical development.
Selected publications
-
Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PH, Jung T. In vivo regulation of interleukin-1 beta in patients with cryopyrin associated periodic syndromes. J Exp Med (2009).
-
Laurent D., Gounarides J.S., Gao J., Boettcher B.R. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes, Obesity, and Metabolism (2009).
-
Singer J.B., Shou Y., Giles F., Kantarjian H.M., Hsu Y., Robeva A.S., Rae P., Weitzman A., Meyer J.M., Dugan M., Ottmann O.G. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 2007 Nov;21(11):2311-5.
Disease areas
Understanding the underlying molecular basis of disease has enabled NIBR to turn scientific insights into medical breakthroughs.
Clinical sciences
Incorporating clinical medicine into its early stage "benchtop" drug discovery.
